Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
Agenus Inc. director Timothy Wright acquired 1,178.7640 Deferred Stock Units on October 1, 2026, at $6.893 per unit under the company's Amended and Restated Directors' Deferred Compensation Plan. His reported direct holdings following the transaction were 29,807.7910 Deferred Stock Units. Under the plan, the units represent common stock to be distributed, typically once he ceases to serve as a director.
Agenus Inc. director Thomas L. Harrison acquired 4,443 shares of common stock on October 1, 2026, under the company’s Board Compensation Election Policy, which allows a director to elect to receive director fees in shares. The reported $6.893 per-share figure is the average closing price across all trading days in the calendar quarter immediately preceding issuance. Harrison’s directly held position after the acquisition was 51,988 shares.
AGENUS INC (AGEN) reported that director Marco Tullio Marcucci received a grant of 7,500 stock options on August 5, 2026. The options have an exercise price of $7.78 per share, expire on August 5, 2036, and relate to 7,500 shares of common stock. According to the award terms, the options vest in three equal annual installments starting on the first anniversary of the grant date, subject to continued service on the Board of Directors. After this grant, Marcucci holds 7,500 options directly.
AGENUS INC (AGEN) reported the initial equity holdings of director Marco Tullio Marcucci. As of August 5, 2026, he is reported as beneficial owner of 4,480 shares of common stock held directly and an additional 1,000 shares held indirectly through his spouse. The filing also notes an Exhibit 24 Power of Attorney authorization.
Agenus Inc. (AGEN) has filed a resale shelf registration covering up to 221,525 shares of common stock for selling stockholders. This includes 217,775 shares issuable upon exercise of amended A, B, C and new D warrants at $3.25 per share, generally expiring on June 25, 2031.
Agenus will not sell shares itself under this prospectus and will receive cash only if the warrants are exercised. Common shares outstanding were 45,161,916 as of September 8, 2026. The company remains a clinical-stage immuno-oncology developer with a $2.14 billion accumulated deficit and an auditor going-concern explanatory paragraph.
AGENUS INC (AGEN) amended a key debt facility through its subsidiary Agenus West, LLC by entering into a Second Loan Modification Agreement with Ocean 1181 LLC. The Borrower issued a Third Amended and Restated Promissory Note that keeps the outstanding principal at $24,750,000, extends the maturity date to November 30, 2029, and sets the interest rate at 13.0% per annum through maturity.
Monthly interest will continue to be paid one-half in cash and one-half in Agenus common stock. The Borrower will pay an extension fee of $247,500, also one-half in cash and one-half in common stock. Shares issued to the lender in connection with this modification are expected to rely on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Regulation D.
Agenus Inc. is registering the potential resale by selling securityholders of up to 77,976,718 shares of common stock. This includes 1,626,015 already outstanding shares, 21,409,212 shares issuable upon exercise of pre-funded warrants, and 54,941,491 shares issuable upon exercise of purchase warrants. Agenus will not receive proceeds from any resale of these shares but will receive cash proceeds if the warrants are exercised. The resale registration follows a July 2026 private placement that issued common stock, pre-funded warrants, and Series A and B warrants with exercise prices of $0.01, $4.02, and $5.03 per share, respectively, at a combined purchase price of $3.69 per unit for gross proceeds of about $85 million. Common shares outstanding were 45,009,670 as of July 31, 2026. Agenus remains a clinical-stage immuno-oncology company focused on its botensilimab/balstilimab program, but its auditors noted that recurring losses and a net capital deficiency raise substantial doubt about its ability to continue as a going concern.
Agenus Inc. approved a special one-time performance-based stock option award for Chairman and CEO Garo H. Armen under its Amended and Restated 2019 Equity Incentive Plan. The award covers 1,971,500 stock options with a 10-year term and an exercise price of $7.78 per share, matching grants made to other managers and set at a premium to the closing price on August 10, 2026. The options are split into five equal tranches, each vesting only if the share price sustains 3x, 4x, 5x, 6x, and 8x the $7.78 measurement price for 30 consecutive days within a five-year performance period, and subject to a minimum three-year service requirement. Unvested options are forfeited upon any employment termination, including retirement and change in control, with limited Committee discretion only in cases of death or disability. Shares acquired on exercise are generally subject to a one-year post-exercise holding period, and the award is subject to the company’s clawback policy.
Agenus Inc granted Chairman and CEO Armen Garo H stock options covering 1,971,500 shares of common stock at an exercise price of $7.78 per share, expiring on August 10, 2036. The award is split into five equal performance-vesting tranches. Each tranche vests only if the share price reaches and sustains, for 30 consecutive days within a five-year performance period, a level equal to 3x, 4x, 5x, 6x, and 8x the $7.78 measurement price, and is also subject to a minimum three-year service requirement.